Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Slides:

Advertisements

Similar presentations

The Skinny on Trans Fats

Advertisements

Reversing Atherosclerosis with Aggressive Lipid Lowering Reversing Atherosclerosis with Aggressive Lipid Lowering Presented at American Heart Association.

Clinical Trial Results. org Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis Stephen J. Nicholls, MBBS, PhD; E.

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

ASTEROID A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden References Nissen et al. Effect.

BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.

Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,

© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.

SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Baseline Characteristics of the Patient Population (n=525) Colin Berry, et al. Circulation 2007;115:

VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:

Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Dual Lipid-Lowering Strategy With Ezetimibe.

Copyleft Clinical Trial Results. You Must Redistribute Slides ASTEROID Trial A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived.

Dufaux, International Journal of Sports Medicine, 1982 TRIGLYCERIDES & TRAINING Increase Decrease No Change Numbers of Studies.

Results of the GLAGOV Trial

Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV Trial SJ Nicholls, H Kassahun, DM Brennan,

NICE –CG 181 Continuum of CVD Risk and its treatment

Results of the GLAGOV Trial

Copyright © 2006 American Medical Association. All rights reserved.

The American College of Cardiology Presented by Dr. Steven E. Nissen

Perelman School of Medicine University of Pennsylvania

Plaque Stabilization by Statin: From EASY-FIT to ESCORT Trial

Flowchart of participant screening, enrollment, withdrawal, and protocol completion Asterisk indicates those with partial or missing data included in analyses.

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

CIMT: a Useful Surrogate for Assessing the Efficacy of new Cardiovascular Drugs? Daniel H. O’Leary, M.D.

The American Heart Association Presented by Dr. Steven E. Nissen

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Oxford Niacin Trial.

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

TNT: Baseline and final LDL cholesterol levels

Arterioscler Thromb Vasc Biol

The ASSERT Study.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.

Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.

Effect of evolocumab on lipoprotein particles

II. assessment of dyslipidemias

Description of studies for pooled analyses

Stephen J. Nicholls, MBBS, PhD; E

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.

Flow of Patients Through the Trial

Flow of Patients Through Trial

Baseline Characteristics, Blood Pressures, and Laboratory Values

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Disposition of Patients in the Atherogenic Dyslipidemia Study

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

PROSPER: trial design

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

TNT diabetes analysis: Baseline and final LDL cholesterol levels

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Adjusted relative risk Adjusted odds ratio

Flow of study participants

III. Treating dyslipidemias

What are the options left?

© The Author(s) Published by Science and Education Publishing.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

ASTEROID: Mean baseline and follow-up levels of LDL and HDL cholesterol Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p HDL-C: baseline (mg/dL) HDL-C: 24 mo (mg/dL) Rosuvastatin 40 mg (n=346) 130.4 60.8 <0.001 43.1 49.0 Nissen SE et al. JAMA 2006; 295: 1556-1565.

ASTEROID: Baseline and follow-up intravascular ultrasound results IVUS-derived measure Baseline 24-month follow-up Absolute change Relative change (%) Mean percent atheroma volume (n=349) 39.6 38.6 - 0.98 NA Mean atheroma volume in the most disease 10-mm subsegment, mm3 (n=319) 65.1 59.0 - 6.1 - 8.5 Mean normalized total atheroma volume, mm3 (n=349) 212.2 197.5 - 14.7 - 6.7 NA=not applicable Nissen SE et al. JAMA 2006; 295: 1556-1565.